Answers are grounded in this paper and cite their sources.
Background and Purpose The neuropeptide calcitonin gene‐related peptide (CGRP) is a well‐established player in migraine. Current CGRP migraine therapeutics were designed to inhibit the canonical CGRP receptor, yet, based on in vitro studies, they can also inhibit to a lesser degree the amylin receptor 1 (AMY 1 ), which CGRP can also activate. This study explores the potential in vivo contributions of these receptors to migraine‐like symptoms in mice. Experimental Approach Receptor contributions were probed using light aversion as a surrogate for photophobia and diarrhoea as a readout for gastrointestinal dysfunction in outbred CD1 mice. Induction of diarrhoea was also measured in C57BL/6 J mice. CGRP and amylin were used as agonists, with two selective antagonists, olcegepant for the canonical CGRP receptor and AC187 for calcitonin receptor (CT)‐based receptors, including AMY 1 . Key Results CGRP and amylin induced light aversion in CD1 mice and diarrhoea in both strains. CGRP‐induced light aversion was partially rescued by AC187, but not olcegepant. Light aversion was fully rescued only by a combination of AC187 and olcegepant. In contrast, olcegepant fully blocked CGRP‐induced diarrhoea, while AC187 only partially blocked at high doses. As a control, olcegepant fully rescued CGRP‐induced periorbital touch hypersensitivity in CD1 mice. Conclusions and Implications More than one receptor contributes to CGRP‐induced light aversion, with a CT‐based receptor unexpectedly playing a major role. In contrast, the canonical CGRP receptor plays a major role in CGRP‐induced diarrhoea. Thus, targeting a CT‐based receptor may reduce photophobia with less adverse gastrointestinal effects in migraine patients.
No takes yet. Share an insight, caveat, or question.
Waite et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: